Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock soared 36% in after-hours trading Wednesday after the biotech company announced a major strategic restructuring plan designed to ensure ...

The announcement at a Hamilton steel plant follows a similar press conference in Ottawa last month when Carney announced a first round of trade protections for Canadian steel mill ...

Investing.com -- Optima Health Group Ltd demonstrated resilience in its F2025 financial results on Tuesday despite facing market headwinds, with strong new business wins and strategic acquisitions ...

The company posted net sales of SEK 6,674 million, representing a 7.2% decrease YoY and coming in 3% below consensus estimates. Adjusted EBITA fell 23% YoY to SEK 438 million, 7% below analyst ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, said Chief Executive Thibaut Mongon has departed and that the company is considering simplifying its portfolio amid a recent sales slump.

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, said Chief Executive Thibaut Mongon has departed and that the company is considering simplifying its portfolio amid a recent sales slump.

Fastenal (FAST) kicked off Q2 earnings this morning with a solid beat: $2.08B in revenue, $0.29 EPS. It’s a small name, but ...

Recent Equity Raise and Debt Restructure Closing paves the way to Major MilestonesKELLOGG, Idaho and VANCOUVER, British ...

US stocks retreated Friday after President Trump threatened Canada with a 35% tariff on its imports to the US and floated higher blanket levies on most trading partners. The S&P 5 ...

Sui (SUI) experienced a significant price increase this week, climbing over 43% to $3.3300, driven by a bullish Grayscale ...

Fitch expects Renesas’ profitability to recover gradually, with a mid-single digit revenue decline in 2025, followed by moderate recovery in 2026-2027. Higher R&D expenses are expected to lower the ...

The company disclosed that despite confidential discussions with potential new and existing investors, no financing transaction has materialized. Karyopharm’s board is now evaluating strategic ...